57 related articles for article (PubMed ID: 1302379)
1. [Effect of CCK receptor antagonists on plasma CCK bioassay].
Sun G; Pan GZ; Ma F; Wen SH; Du SF
Sheng Li Xue Bao; 1992 Dec; 44(6):609-13. PubMed ID: 1302379
[TBL] [Abstract][Full Text] [Related]
2. [Bioassay for plasma cholecystokinin bioactivity].
Sun G
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1991 Dec; 13(6):417-21. PubMed ID: 1724414
[TBL] [Abstract][Full Text] [Related]
3. Metabolism of cholecystokinin-33 in vivo: effect of L-364,718, a CCK receptor antagonist.
Hosotani R; Doi R; Gu Y; Wada M; Inoue K; Fujii N; Rayford PL; Imamura M
Ann Clin Lab Sci; 1994; 24(4):346-54. PubMed ID: 7944271
[TBL] [Abstract][Full Text] [Related]
4. [Plasma cholecystokinin level in chronic pancreatitis].
Mössner J; Back T; Regner U; Fischbach W
Z Gastroenterol; 1989 Aug; 27(8):401-5. PubMed ID: 2609704
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a new CCK antagonist, L364,718: in vitro and in vivo studies.
Louie DS; Liang JP; Owyang C
Am J Physiol; 1988 Sep; 255(3 Pt 1):G261-6. PubMed ID: 2458681
[TBL] [Abstract][Full Text] [Related]
6. Determination of plasma cholecystokinin (CCK) concentrations by bioassay and radioimmunoassay in man. A critical evaluation.
Höcker M; Schmidt WE; Creutzfeldt W; Choudhury AR; Nustede R; Schafmayer A; Fölsch UR
Regul Pept; 1992 Feb; 37(3):255-69. PubMed ID: 1557514
[TBL] [Abstract][Full Text] [Related]
7. Effects of three different cholecystokinin receptor antagonists on basal and stimulated insulin and glucagon secretion in mice.
Karlsson S; Ahrén B
Acta Physiol Scand; 1989 Mar; 135(3):271-8. PubMed ID: 2648765
[TBL] [Abstract][Full Text] [Related]
8. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).
Lin CW; Holladay MW; Barrett RW; Wolfram CA; Miller TR; Witte D; Kerwin JF; Wagenaar F; Nadzan AM
Mol Pharmacol; 1989 Dec; 36(6):881-6. PubMed ID: 2601685
[TBL] [Abstract][Full Text] [Related]
9. Cholecystokinin type A and type B receptor antagonists produce opposing effects on cholecystokinin-stimulated beta-endorphin secretion from the rat pituitary.
Millington WR; Mueller GP; Lavigne GJ
J Pharmacol Exp Ther; 1992 May; 261(2):454-61. PubMed ID: 1578360
[TBL] [Abstract][Full Text] [Related]
10. Asperlicin: a unique nonpeptide cholecystokinin antagonist.
Zucker KA; Adrian TE; Zdon MJ; Ballantyne GH; Modlin IM
Surgery; 1987 Aug; 102(2):163-70. PubMed ID: 2441481
[TBL] [Abstract][Full Text] [Related]
11. Combined dose-ratio analysis of cholecystokinin receptor antagonists, devazepide, lorglumide and loxiglumide in the guinea-pig gall bladder.
Bishop LA; Gerskowitch VP; Hull RA; Shankley NP; Black JW
Br J Pharmacol; 1992 May; 106(1):61-6. PubMed ID: 1504732
[TBL] [Abstract][Full Text] [Related]
12. Effect of two new cholecystokinin antagonists on gallbladder emptying in opossums.
Hanyu N; Dodds WJ; Layman RD; Hogan WJ; Colton DG
Am J Physiol; 1991 Feb; 260(2 Pt 1):G258-64. PubMed ID: 1996645
[TBL] [Abstract][Full Text] [Related]
13. CCK-receptor antagonists attenuate suppression of sham feeding by intestinal nutrients.
Yox DP; Brenner L; Ritter RC
Am J Physiol; 1992 Apr; 262(4 Pt 2):R554-61. PubMed ID: 1373576
[TBL] [Abstract][Full Text] [Related]
14. Oral glucose ingestion stimulates cholecystokinin release in normal subjects and patients with non-insulin-dependent diabetes mellitus.
Hasegawa H; Shirohara H; Okabayashi Y; Nakamura T; Fujii M; Koide M; Otsuki M
Metabolism; 1996 Feb; 45(2):196-202. PubMed ID: 8596489
[TBL] [Abstract][Full Text] [Related]
15. CCK-A antagonists: which and how.
D'Amato M; Rovati LC
Eur J Clin Invest; 1995 Mar; 25(3):213-4. PubMed ID: 7781670
[No Abstract] [Full Text] [Related]
16. Bile acids in human plasma interfere with cholecystokinin bioassay using dispersed pancreatic acini.
Miyasaka K; Funakoshi A; Matsumoto M; Nakamura R; Sakamoto S; Sakai H; Kitani K
Dig Dis Sci; 1991 Mar; 36(3):310-6. PubMed ID: 1995267
[TBL] [Abstract][Full Text] [Related]
17. Effects of diet and the cholecystokinin antagonist; devazepide (L364,718) on CCK mRNA, and tissue and plasma CCK concentrations.
Playford RJ; King AW; Deprez PH; De-Belleroche J; Freeman TC; Calam J
Eur J Clin Invest; 1993 Oct; 23(10):641-7. PubMed ID: 8281982
[TBL] [Abstract][Full Text] [Related]
18. Anti-exploratory effect of N-methyl-D-aspartate in elevated plus-maze. Involvement of NMDA and CCK receptors.
Vasar E; Harro J; Lang A; Soosaar A; Oöpik T; Kôks S; Sihver S; Volke V
Eur Neuropsychopharmacol; 1993 Mar; 3(1):63-73. PubMed ID: 8471831
[TBL] [Abstract][Full Text] [Related]
19. The cholecystokinin receptor antagonist L364,718 increases food intake in the rat by attenuation of the action of endogenous cholecystokinin.
Hewson G; Leighton GE; Hill RG; Hughes J
Br J Pharmacol; 1988 Jan; 93(1):79-84. PubMed ID: 3349234
[TBL] [Abstract][Full Text] [Related]
20. Cholecystokinin receptors and memory: a radial maze study.
Harro J; Oreland L
Pharmacol Biochem Behav; 1993 Mar; 44(3):509-17. PubMed ID: 8451255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
